Diagnostic value of methylated branched chain amino acid transaminase 1/IKAROS family zinc finger 1 for colorectal cancer

Figure 1 Detailed process of literature identification and screening.

Figure 2 Overview of applicability concerns and the risk of bias of included studies according to the Cochrane Collaboration’s Diagnostic Accuracy Studies Quality Assessment 2 tool.

Figure 3 Pooled analysis of the diagnostic accuracy of methylated branched chain amino acid transaminase 1/IKAROS family zinc finger 1 in plasma for patients with colorectal cancer. A: Sensitivity; B: Specificity; C: Summary receiver operating characteristic curve. SROC: Summary receiver operating characteristics.

Figure 4 The Sensitivity of methylated branched chain amino acid transaminase 1/IKAROS family zinc finger 1 in plasma for patients with colorectal cancer at different stages. A: I stage; B: II stage; C: III stage; D: IV stage.

Figure 5 Sensitivity analysis of the included studies.

Figure 6 Publication bias analysis of the included studies by Deeks’ funnel plot asymmetric linear regression test.